The MarketWatch News Department was not involved in the creation of this content. -- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment of non-cirrhotic ...
The FDA granted breakthrough therapy designation to efimosfermin — an investigational, once-monthly fibroblast growth factor ...
A biopharmaceutical company focused exclusively on metabolic dysfunction-associated steatohepatitis (MASH), having secured ...
Liver fibrosis may be diagnosed and staged — no fibrosis (stage F0), mild fibrosis (F1), significant fibrosis (F2), advanced fibrosis (F3), and cirrhosis (F4) — with the use of clinical parameters and ...
GSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA PRIME designations to treat MASH: London, UK Wednesday, April 29, 2026, 09:00 Hrs ...
Introduction The global rise in obesity and metabolic syndrome has increased metabolic dysfunction-associated steatotic liver disease (MASLD) incidence. Owing to its high prevalence and the emergence ...
Resolution of steatohepatitis with no worsening of liver fibrosis was achieved in 63% of patients taking semaglutide vs 34% taking placebo at week 72. The Food and Drug Administration (FDA) has ...
For many years, it was believed that when an individual develops liver scarring, it can not be reversed. Today, we know that ...
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra Poster of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results